Our CLINICAL TRIAL is now Recruiting Type 2 Diabetes Patients
- May 24, 2021
- 1 min read
Concenter Biopharma, together with the SHEBA Medical Center in Israel recently began recruiting patients for the clinical trial using the company's Zygosid-50 Drug. The Trial is examining the Safety and Efficacy of Zygosid-50 Administered by Sub-Cutaneous Injection for Glycemic Control of Patients with Type 2 Diabetes Mellitus.
Inclusion criteria in the trial include:
1.Male or female subjects with T2DM.
2.Age: 30 - 80 years.
3.10.5%>HbA1c >7.5%, and Hb>14 g/dl for men, and Hb>12 g/dl for women.
4.Stable diabetes treatment for the last 3 months.
5.Treatment with any anti-diabetic drugs except insulin.
6.BMI of 27 to 35 If you think you are interested in hearing more abbot the trial please contact our Chief Medical Officer - Prof. Amir Elami: amir@concenterbiopharma.com
Information (Hebrew) from the Israeli Ministry of Health website: https://my.health.gov.il/CliniTrials/Pages/MOH_2021-04-06_009876.aspx
Such an important opportunity for Type 2 Diabetes patients to contribute to medical research. Just as medical billing and collections help healthcare operations run smoothly, clinical trials support future treatments. Wishing success with recruitment and positive outcomes for participants
God bless you millions of people just pray for this till you guys find cures for us(diabetes)👏👏👏🙏🙏🙏
God bless